Abstract
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
AIDS Dementia Complex / drug therapy*
-
AIDS Dementia Complex / metabolism
-
AIDS Dementia Complex / psychology
-
Adult
-
Anti-Retroviral Agents / therapeutic use
-
CD4 Lymphocyte Count
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
HIV Infections / psychology
-
HIV-1*
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Valproic Acid / therapeutic use*
Substances
-
Anti-Retroviral Agents
-
Valproic Acid